Chemotherapy and the Immune System PDF Download

Author: L. H. Chappell
Publisher: Cambridge University Press
ISBN: 9780521448352
Category : Medical
Languages : en
Pages : 116

View

Book Description
This specially commissioned text covers a range of topics relating to chemotherapy and the immune system.

Author: Enrico Mihich
Publisher: Elsevier
ISBN: 1483259005
Category : Health & Fitness
Languages : en
Pages : 415

View

Book Description
Immunity, Cancer, and Chemotherapy focuses on the interference of drugs on antibody response and transplantation immunity. The selection first offers information on the effects of immunosuppressive drugs on cellular changes after antigenic stimulation and specialized cell function in the lymphoid and reticuloendothelial cell series. Topics include effects of immunosuppressive drugs on the sensitization process; cellular changes in lymphoid tissue following sensitization; and demonstration of differences in antigen handling among cells of the reticuloendothelial system. The text also takes a look at allogeneic inhibition and its possible relation to cell-bound immunity in vitro and the effects of immunosuppressive drugs at various stages of differentiation of immunologically competent cells. The publication examines a study of antibody-containing cells in the course of immunization and cellular differentiation during immune responses studied with electron microscope and radioautography. The text also elaborates on ambiguity in the translation of genetic code into proteins, induced by aminoglycoside antibiotics and immunosuppressive agents and cellular kinetics of immune response. The selection is a dependable source of information for readers interested in effects of drugs on antibody response and transplantation immunity.

Author: Gerhard Pulverer
Publisher:
ISBN:
Category : Anti-infective agents
Languages : en
Pages : 264

View

Book Description

Author: Gabriele Multhoff
Publisher: Frontiers E-books
ISBN: 2889191397
Category :
Languages : en
Pages : 131

View

Book Description
Numerous developments in molecular biology have led to an explosive growth in the knowledge underlying mechanisms of carcinogenesis, cell signalling, tumor progression and development of metastasis. However, cure of cancer is still hampered by the inherited capacity of tumors to become resistant to standard therapies, to metastasize from their initial location and to proliferate in other tissue compartments. Radiotherapy is one of the main treatment modalities to achieve locoregional tumor control. However, the treatment of distant metastases further remains to be a challenge. In this special topic we are interested to elucidate immunological aspects which are initiated and affected by radiotherapy. We also aim to describe the development of innovative immunological strategies from a preclinical stage to clinical application which could be combined with standard radiotherapeutic approaches. A special interest will also deal with the effects of radiotherapy on tumor initiating cells as well as on the tumor microenvironment. Last but not least the effects of different irradiation sources and qualities such as photones, protones and heavy ions will be analyzed with respect to immunological outcome.

Author: Haidong Dong
Publisher: Springer Nature
ISBN: 3031594754
Category :
Languages : en
Pages : 228

View

Book Description

Author: Paul D. Rennert
Publisher: Springer
ISBN: 3319298275
Category : Medical
Languages : en
Pages : 285

View

Book Description
Cancer care is undergoing a radical transformation as novel technologies are directed toward new treatments and personalized medicine. The most dramatic advances in the treatment of cancer have come from therapeutics that augment the immune response to tumors. The immune checkpoint inhibitors are the best-known and most highly advanced examples of Immune Therapeutics targeting tumor cells and include approved antibody drugs directed at the cell surface proteins CTLA4 and PD-1. These are now considered foundational treatments for several solid tumor indications, and that list of indications is growing quickly. More broadly, antibodies have become workhorse molecules across the entire immunotherapy landscape. Antibodies to novel targets modulate the activity of diverse immune cell regulatory proteins. Engineered antibodies can induce tumor cell death or expose tumor cells to poisonous toxins (ADCC and ADC, respectively). Bi-specific antibodies can engage multiple tumor targets simultaneously, or can redirect lymphocytes to attack tumor cells. The antigen-binding domains within antibodies can be spliced onto cell stimulatory domains and transduced into T cells or NK cells, creating remarkable tumor-specific cellular therapeutics (CAR-T, CAR-NK). Beyond antibody-based therapies there are highly diverse and differentiated technology tool kits being applied to immunotherapy. Small molecule drugs are being developed to attack the tumor microenvironment, novel tumor vaccine approaches are showing great promise, patient lymphocytes are being isolated, expanded and reintroduced to patients, gene-editing techniques are becoming widely deployed, and a vast number of new tumor targets, and mutated tumor proteins (neoantigens), are being discovered. The past decade has seen unprecedented success in the treatment of diverse cancers. The authors of this volume have been asked to not only review progress to date, but importantly, to look ahead, and anticipate the evolution of cancer treatment across diverse Immune Therapeutic approaches. Our hypothesis is that the advances we are seeing across the immunotherapy landscape will further evolve and synergize, leading us finally to outright cures for many cancers.

Author: Abhishek D Garg
Publisher: Frontiers Media SA
ISBN: 2889198383
Category : Immunologic diseases. Allergy
Languages : en
Pages : 147

View

Book Description
Classically, anti-cancer therapies have always been applied with the primary aim of tumor debulking achieved through widespread induction of cancer cell death. While the role of host immune system is frequently considered as host protective in various (antigen-bearing) pathologies or infections yet in case of cancer overtime it was proposed that the host immune system either plays no role in therapeutic efficacy or plays a limited role that is therapeutically unemployable. The concept that the immune system is dispensable for the efficacy of anticancer therapies lingered on for a substantial amount of time; not only because evidence supporting the claim that anti-cancer immunity played a role were mainly contradictory, but also largely because it was considered acceptable (and sometimes still is) to test anticancer therapies in immunodeficient mice (i.e. SCID/athymic mice lacking adaptive immune system). This latter practice played a detrimental role in appreciating the role of anticancer immunity in cancer therapy. This scenario is epitomized by the fact that for a long time the very existence of cancer-associated antigens or cancer-associated ‘danger signaling’ remained controversial. However, over last several years this dogmatic view has been considerably modified. The existence of cancer-associated antigens and ‘danger signaling’ has been proven to be incontrovertible. These developments have together paved way for the establishment of the attractive concept of “immunogenic cell death” (ICD). It has been established that a restricted class of chemotherapeutics/targeted therapeutics, radiotherapy, photodynamic therapy and certain oncolytic viruses can induce a form of cancer cell death called ICD which is accompanied by spatiotemporally defined emission of danger signals. These danger signals along with other factors help cancer cells undergoing ICD to activate host innate immune cells, which in turn activate T cell-based immunity that helps eradicate live (or residual) surviving cancer cells. The emergence of ICD has been marred by some controversy. ICD has been criticized to be either experimental model or setting-specific or mostly a concept based on rodent studies that may have very limited implications for clinical application. However, in recent times it has emerged (through mainly retrospective or prognostic studies) that ICD can work in various human clinical settings hinting towards clinical applicability of ICD. However a widespread consensus on this issue is still transitional. In the current Research Topic we aimed to organize and intensify a discussion that strives to bring together the academic and clinical research community in order to provide a background to the current state-of-the-art in ICD associated bench-side research and to initiate fruitful discussions on present and future prospects of ICD translating towards the clinical, bedside reality.

Author: Alan P. Lyss
Publisher: John Wiley & Sons
ISBN: 1118069994
Category : Health & Fitness
Languages : en
Pages : 384

View

Book Description
An informative, compassionate guide for cancer patients and their loved ones Each year, more than 1 million people get treated for cancer, and most of these will undergo chemotherapy, radiation therapy, or both. This reassuring, optimistic guide helps people get a handle on treatment options and explains in plain English how chemotherapy and radiation therapy really work. It offers detailed advice on how to alleviate and cope with side effects-which range from hair loss to nausea to anemia-and describes how good nutrition, meditation, support groups, and other techniques and resources can help in the recovery process.

Author: Lisa H. Butterfield, PhD
Publisher: Springer Publishing Company
ISBN: 1617052736
Category : Medical
Languages : en
Pages : 921

View

Book Description
“Drs. Butterfield, Kaufman and Marincola on behalf of the SITC have created a comprehensive must-have resource covering the basic and translational science behind approved and investigational immune therapies, and disease-by-disease clinical application of the therapies, written by leaders in the field. The textbook will be highly valuable reading for those just entering the field and for experienced scientists and clinicians looking to expand their knowledge base.” —Mario Sznol, MD, Professor of Medicine (Medical Oncology), Yale School of Medicine, New Haven, Connecticut “Given the important and exciting advances in cancer immunotherapy, it is not surprising that there is no dearth of books on the subject. Despite the competition, however, this book is a unique masterpiece and a must-have comprehensive resource for anyone interested in this area and for every medical library.” Score: 100, 5 Stars, Doody’s Medical Reviews Cancer Immunotherapy Principles and Practice, from the Society for Immunotherapy of Cancer (SITC), is the authoritative reference on cancer immunobiology and the immunotherapy treatments that harness the immune system to combat malignant disease. Featuring five sections and over 50 chapters covering the Basic Principles of Tumor Immunology, Cancer Immunotherapy Targets and Classes, Immune Function in Cancer Patients, Disease-Specific Treatments and Outcomes, and Regulatory Aspects of Cancer Immunotherapy, this book covers all major topics that have shaped the development of immunotherapy and propelled it to its current place at the forefront of cancer treatment innovation. This volume is a comprehensive resource for oncologists and fellows, immunologists, cancer researchers, and related practitioners seeking understanding of the basic science and clinical applications of cancer immunotherapy. As well as presenting the evidence for immune-based cancer treatment, it positions immunotherapy in the context of other available cancer treatments and provides data on response rates, risks, and toxicities across a variety of diseases. Filled with detailed tables, and instructive illustrations, as well as key points for quick reference, Cancer Immunotherapy Principles and Practice simplifies a challenging and dynamic subject. KEY FEATURES Clearly summarizes the basic principles and research supporting cancer immunotherapy clinical translation Contains expert guidance and treatment strategies for all immunotherapy classes and agents, including cell-based therapies, monoclonal antibodies, cytokine therapies, checkpoint inhibitors, oncolytic viruses, adjuvant approaches, and treatment combinations Includes expert perspectives from leading authorities in the field Provides information on all FDA-approved immunotherapies, including clinical management and outcome data Discusses clinical aspects of immunotherapy for individual cancer types, including melanoma and other skin cancers, lung cancers, gynecologic cancers, gastrointestinal cancers, hematologic cancers, genitourinary cancers, head and neck cancers, sarcomas, brain and other CNS cancers, breast cancer, and pediatric malignancies. Explains regulatory aspects behind the development and approval of immunotherapy drugs

Author: T. H. M. Stewart
Publisher: CRC Press
ISBN: 1351367722
Category : Medical
Languages : en
Pages : 387

View

Book Description
Cellular Immune Mechanisms and Tumor Dormancy features the work of internationally recognized experts from various disciplines as they discuss the phenomenon of tumor dormancy in humans. Animal models are described in which cellular and molecular components of the immune control of dormancy have been identified, and the relevance of these models to human cancer patients is recognized. Data derived from studies of organ transplantation, adjuvant chemotherapy, radiotherapy, anaesthesia, surgery, and whole blood transfusion is presented to show the vulnerability of cellular mechanisms maintaining dormancy. The potential for increasing the incidence of dormancy in micro metastases is also shown for non-small cell lung cancer, lymphoma, and leukemia. Cellular Immune Mechanisms and Tumor Dormancy is an important reference volume that will benefit researchers from many disciplines, including immunologists, pathologists, surgeons, and clinicians